2 active not recruiting, 2 completed, 2 not yet recruiting, 1 recruiting. 10 Phase 2, 5 Phase 1, 1 Phase 3.
Follow azeliragon: new trials by email Literature Review of azeliragon trials Research Report on azeliragon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer Azeliragon, T-DXd - T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 27 | 2026-12-01 | 2026-08-25 |
| Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas Dexamethasone, Azeliragon - High-grade Gliomas (HGG) | Phase 2 | Not yet recruiting | Akshitkumar MIstry | 80 | 2026-10-01 | 2026-07-09 |
| Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Azeliragon, Stereotactic radiosurgery, Corticosteroid - Cancer, Metastasis | Phase 1 / Phase 2 | Suspended | Baptist Health South Florida | 46 | 2023-11-17 | 2026-06-16 |
| Azeliragon in MGMT Unmethylated Glioblastoma Azeliragon - Glioblastoma | Phase 2 | Active not recruiting | Cantex Pharmaceuticals | 30 | 2023-09-12 | 2026-03-31 |
| Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma | Phase 1 / Phase 2 | Completed | Cantex Pharmaceuticals | 33 | 2023-09-05 | 2026-10-19 |
| RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer TTP488, ddAC/ddT, TC - Cancer Related Cognitive Decline, Non-metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Georgetown University | 48 | 2023-06-06 | 2025-12-24 |
| Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer Azeliragon - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Cantex Pharmaceuticals | 30 | 2023-06-01 | 2024-06-14 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia Azeliragon, Placebo - COVID-19 | Phase 2 / Phase 3 | Active not recruiting | The University of Texas Medical Branch, Galveston | 144 | 2023-05-04 | 2025-03-03 |
| Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance Azeliragon, Placebo - Alzheimer Disease | Phase 2 | Terminated | vTv Therapeutics | 43 | 2019-06-27 | 2022-01-21 |
| 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria PF-04494700 (TTP488), Placebo - Diabetic Nephropathy | Phase 2 | Completed | Pfizer | 110 | 2006-02-01 | 2009-10-01 |
Glioblastoma (2) · Acute Kidney Injury (1) · Alzheimer Disease (1) · Brain Neoplasms (1) · COVID-19 (1) · Diabetic Nephropathies (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Cantex Pharmaceuticals (3) · Akshitkumar MIstry (1) · Baptist Health South Florida (1) · Georgetown University (1) · Pfizer (1) · The Methodist Hospital Research Institute (1) · The University of Texas Medical Branch, Galveston (1) · vTv Therapeutics (1)
United States (7) · Canada (2) · Spain (1)
Akshitkumar M Mistry, MD (1) · Andrew Hendifar, MD (1) · Candace Mainor, MD (1) · Lucas S. Blanton, MD (1) · Minesh Mehta, M.D. (1) · Stephen G Marcus, MD (1)